Dihydropyrimidine Dehydrogenase Deficiency Latest Advances

Long-term storage stability of uracil in plasma.

Journal: Scandinavian journal of clinical and laboratory investigation

Published: August 12, 2026

Fatal 5-Fluorouracil Toxicity With Hyperammonemic Encephalopathy, Lactic Acidosis, and Pneumatosis Intestinalis Despite Uridine Triacetate Rescue: A Case Report.

Journal: Cureus

Published: June 28, 2026

Impact of renal impairment, hepatic function, and circadian rhythm on pre-treatment plasma uracil levels.

Journal: Clinica chimica acta; international journal of clinical chemistry

Published: June 04, 2026

Capecitabine-induced pneumonitis: a rare case report and literature review.

Journal: Anti-cancer drugs

Published: May 06, 2026

Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report.

Journal: Frontiers in pharmacology

Published: April 27, 2026

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 18, 2026

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Journal: JCO oncology practice

Published: March 26, 2026

Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Capillary dried blood microsampling is not suited for dihydropyrimidine dehydrogenase (DPD) phenotyping.

Journal: Clinical chemistry and laboratory medicine

Published: January 27, 2026

Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing.

Journal: Pharmacogenomics

Published: January 16, 2026

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Journal: Expert opinion on drug metabolism & toxicology

Published: January 08, 2026

Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.

Journal: JCO global oncology

Published: November 19, 2025

Dihydropyrimidine Dehydrogenase Deficiency Latest Advances

Find the Latest Research About Dihydropyrimidine Dehydrogenase Deficiency

Long-term storage stability of uracil in plasma.

Long-term storage stability of uracil in plasma.

Fatal 5-Fluorouracil Toxicity With Hyperammonemic Encephalopathy, Lactic Acidosis, and Pneumatosis Intestinalis Despite Uridine Triacetate Rescue: A Case Report.

Fatal 5-Fluorouracil Toxicity With Hyperammonemic Encephalopathy, Lactic Acidosis, and Pneumatosis Intestinalis Despite Uridine Triacetate Rescue: A Case Report.

Impact of renal impairment, hepatic function, and circadian rhythm on pre-treatment plasma uracil levels.

Impact of renal impairment, hepatic function, and circadian rhythm on pre-treatment plasma uracil levels.

Capecitabine-induced pneumonitis: a rare case report and literature review.

Capecitabine-induced pneumonitis: a rare case report and literature review.

Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report.

Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report.

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer.

Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer.

Capillary dried blood microsampling is not suited for dihydropyrimidine dehydrogenase (DPD) phenotyping.

Capillary dried blood microsampling is not suited for dihydropyrimidine dehydrogenase (DPD) phenotyping.

Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing.

Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing.

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.

Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.